ClinicalTrials.govpublic full text
ALTA-1L Study: A Study of Brigatinib Versus Crizotinib in Anaplastic Lymphoma Kinase Positive (ALK+) Advanced Non-small Cell Lung Cancer (NSCLC) Participants
non-small cell lung cancer, lung cancer, advanced malignancies, carcinoma, non-small cell lung carcinoma, epithelial lung cancer, squamous cell carcinoma, large cell carcinoma, adenocarcinoma, anaplastic lymphoma kinase (alk), advanced cancers, brigatinib
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Record · ID 873417
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.